C-Bridge Capital, BioBAY Lead $38M Series A Round In Biopharmaceutical Service Firm CMAB BioPharm

Login to View

Chinese private equity firm C-Bridge Capital has teamed up with Suzhou bio-medical and medical high-tech park BioBAY in leading a US$38 million series A round in CMAB BioPharm, a contract development and manufacturing organization (CDMO) providing comprehensive pharmaceutical services to biopharma companies.

China Money Network

Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech

Want to read this important story?

Access Over 11,000 stories and data posts over the past 8 years!

Register Now

Already have an account or paid subscription? Log in